Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.17.

Several research analysts have recently weighed in on SVRA shares. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. HC Wainwright cut their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday.

Hedge Funds Weigh In On Savara

A number of hedge funds have recently modified their holdings of SVRA. CANADA LIFE ASSURANCE Co bought a new position in shares of Savara in the first quarter worth approximately $35,000. Choreo LLC bought a new position in shares of Savara in the second quarter worth approximately $59,000. DRW Securities LLC purchased a new position in shares of Savara in the second quarter worth $62,000. Principal Financial Group Inc. lifted its holdings in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC purchased a new position in shares of Savara in the second quarter worth $105,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Down 1.8 %

SVRA opened at $3.19 on Tuesday. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a 50 day moving average price of $3.93 and a 200-day moving average price of $4.21. Savara has a twelve month low of $3.09 and a twelve month high of $5.70. The stock has a market capitalization of $525.08 million, a price-to-earnings ratio of -7.60 and a beta of 1.02.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Equities research analysts forecast that Savara will post -0.44 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.